Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

During the 2026 J.P. Morgan Healthcare Conference (JPM), the 2026 China FIC Innovation & Collaboration Summit was successfully held in San Francisco, the United States. Organized by the ZFIC Alliance, ...

Celltrion outlines a blueprint for innovative drug development built on its antibody expertiseThe company highlights its ...

This agreement reinforces Credence’s role as a trusted partner to the pharmaceutical industry in advancing patient care. This ...

Samsung Epis Holdings, the holding company of biosimilar drug developer Samsung Bioepis Co., has pledged to put more effort ...

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE ...

Charles River Laboratories will pay $60 million for the remaining shares of PathoQuest and $510 million for acquiring K.F.

I am excited to welcome Jim to Aligos as our Chief Commercial Officer who will spearhead our commercial readiness efforts,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive ...

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...

Genialis, the RNA biomarker company, today announced that Swiss-based biopharmaceutical company Debiopharm has deployed the Genialis™ Expressions software platform within its cloud infrastructure to ...

Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support ...

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (“Shuttle Pharma” or the “Company”), applauds the state of Utah which has become ...